The combination of pyrotinib with neoadjuvant chemotherapy and trastuzumab in HER2‐positive breast cancer has been investigated in several clinical trials as summarized in Table S4, with tpCR rates ranging from 41.0% to 73.7% [8, 10, 11, 12, 13]. The gene discussed is ERBB2; the disease is breast carcinoma.